1. Home
  2. CELC vs CHEF Comparison

CELC vs CHEF Comparison

Compare CELC & CHEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CELC
  • CHEF
  • Stock Information
  • Founded
  • CELC 2011
  • CHEF 1985
  • Country
  • CELC United States
  • CHEF United States
  • Employees
  • CELC N/A
  • CHEF N/A
  • Industry
  • CELC Medical Specialities
  • CHEF Food Distributors
  • Sector
  • CELC Health Care
  • CHEF Consumer Discretionary
  • Exchange
  • CELC Nasdaq
  • CHEF Nasdaq
  • Market Cap
  • CELC 2.3B
  • CHEF 2.6B
  • IPO Year
  • CELC 2017
  • CHEF 2011
  • Fundamental
  • Price
  • CELC $50.51
  • CHEF $55.44
  • Analyst Decision
  • CELC Strong Buy
  • CHEF Strong Buy
  • Analyst Count
  • CELC 6
  • CHEF 7
  • Target Price
  • CELC $63.00
  • CHEF $68.86
  • AVG Volume (30 Days)
  • CELC 1.0M
  • CHEF 550.0K
  • Earning Date
  • CELC 11-13-2025
  • CHEF 10-29-2025
  • Dividend Yield
  • CELC N/A
  • CHEF N/A
  • EPS Growth
  • CELC N/A
  • CHEF 63.82
  • EPS
  • CELC N/A
  • CHEF 1.62
  • Revenue
  • CELC N/A
  • CHEF $3,950,674,000.00
  • Revenue This Year
  • CELC N/A
  • CHEF $9.06
  • Revenue Next Year
  • CELC N/A
  • CHEF $7.54
  • P/E Ratio
  • CELC N/A
  • CHEF $34.20
  • Revenue Growth
  • CELC N/A
  • CHEF 7.90
  • 52 Week Low
  • CELC $7.58
  • CHEF $38.36
  • 52 Week High
  • CELC $63.06
  • CHEF $68.94
  • Technical
  • Relative Strength Index (RSI)
  • CELC 49.45
  • CHEF 31.60
  • Support Level
  • CELC $44.42
  • CHEF $53.20
  • Resistance Level
  • CELC $52.76
  • CHEF $58.87
  • Average True Range (ATR)
  • CELC 3.10
  • CHEF 2.20
  • MACD
  • CELC -1.11
  • CHEF -0.92
  • Stochastic Oscillator
  • CELC 51.39
  • CHEF 14.83

About CELC Celcuity Inc.

Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.

About CHEF The Chefs' Warehouse Inc.

The Chefs' Warehouse Inc is a specialty food distributor in metropolitan areas across the United States and Canada. The company's product portfolio is comprised of imported and local specialty food products such as cheese, cooking oils, chocolates, dried food, baking products, meats, and other food products. It operates via one reporting segment called Food Product Distribution. Operations are concentrated on the east, midwest, and west coasts of the U.S. The company provides service to restaurants, clubs, hotels, caterers, schools, bakeries, casinos, and specialty food stores.

Share on Social Networks: